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Abstract
INTRODUCTION: Glucose transporter 1 (Glut-1) is a facilitative glucose transporter expressed in many cancers includ-
ing breast cancer. Basal-like breast cancer (BLBC) is a high-risk disease associated with poor prognosis and lacks the
benefit of targeted therapy. The aim of this study was to characterize the immunohistochemical (IHC) expression of
Glut-1 in patients with BLBC compared with non-BLBC. MATERIALS AND METHODS: We identified 523 cases of
invasive breast carcinoma from our database. The clinicopathologic findings and the biologic markers including
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) statuswere
reviewed. IHC stains for cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), p53, and Glut-1 were per-
formed on tissuemicroarray using standard procedures. BLBCwas defined as ER−, PR−, Her2−, and CK5/6+ and/or
EGFR+. RESULTS: Of informative cases, 14.7% were categorized as BLBC versus 85.3% as non-BLBC. Glut-1 was
expressed in 42 (76.4%) of 55 BLBCs, whereas only 55 (23.8%) of 231 non-BLBCs showed immunostaining for Glut-1
(P < .001). Overall, Glut-1 expression was significantly associated with high histologic grade, ER negativity, PR neg-
ativity, CK5/6 positivity, EGFR expression, and high p53 expression (P < .001). However, there was no correlation
between Glut-1 immunostaining and patient’s outcome. CONCLUSIONS: Our results show that Glut-1 is significantly
associated with BLBC and might be a potential therapeutic target for this aggressive subgroup of breast cancer, and
this warrants further investigations.
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Introduction
Recent gene expression profiling studies on breast tumors have iden-
tified five distinct subtypes of breast cancer (luminal A, luminal B,
human epidermal growth factor receptor 2 [HER2] overexpressing,
basal-like, and normal-like) with different clinical outcomes [1–3].
Luminal (steroid receptor–positive) tumors have a superior outcome
compared with HER2 or basal-like subtypes. Basal-like breast cancer
(BLBC) is characterized by constitutive expression of genes usually
found in normal basal/myoepithelial cells of the breast [4].
There is no consensus on how to define BLBC by immunohisto-
chemical (IHC) markers. The majority of BLBCs lack the expression of
estrogen receptor (ER), progesterone receptor (PR), and Her2 protein
overexpression [5–7]. BLBC also has been characterized by the expres-
sion of basal cytokeratins (CKs) 5/6 and 17, epidermal growth factor
receptor (EGFR), c-kit, and vascular endothelial growth factor (VEGF)
[1,7,8]. Nielsen et al. [7] have developed an IHC panel for identifying
BLBCs on the basis of a comparison between the transcriptomic and
IHC profiles. According to this definition, BLBCs are negative for ER
and HER2 and positive for CK5/6 and/or EGFR. Conversely, others
have proposed that a proportion of BLBCs may be positive for ER and
Her2 [9,10].
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BLBC has been a particular focus of attention because this pheno-
type has no confirmed therapeutic molecular target and has a poor
prognosis [4–7]. Identification of new biological key pathways driv-
ing BLBC might aid in finding targets of potential interest for thera-
peutic blockade.
Tumor hypoxia is a key factor driving the development of malig-
nancy. The presence of hypoxia in tumors is known to lead to resis-
tance to radiotherapy and chemotherapy and is associated with a more
aggressive phenotype with an increased propensity for metastases
[11,12]. This latter characteristic is thought to be related to the increased
expression of a number of proteins acting through the hypoxia-inducible
factor 1 (HIF-1) pathway, which allows tumor cells to survive the harsh
tumor microenvironment. Glucose transporter 1 (Glut-1) is one of the
proteins upregulated in hypoxic conditions [13], and its expression is
dually controlled through HIF-1 and in response to reduced oxidative
phosphorylation [14]. Glut-1 is one of the facilitative cell surface glucose
transporter family that function as an energy-independent system for
transport of glucose down a concentration gradient [15]. Glut-1 is not
detectable in a large proportion of cells from normal tissues except for
erythrocytes, germinal cells of the testis, renal tubules, perineurium of
peripheral nerves, and endothelial cells in blood-brain barrier vessels
[16]. In contrast, overexpression of Glut-1 has been described in various
malignant tumors and was associated with enhanced tumor aggressive-
ness and poor outcome [17–19]. It has been previously demonstrated
that Glut-1 expression was increased in poorly differentiated breast car-
cinoma and associated with high proliferative activity, increased inva-
siveness, and aggressive behavior [20–22].
To our knowledge, published data on the expression of Glut-1 in
BLBC are scarce. Therefore, the main objective of this study was to
characterize the IHC expression of Glut-1 in patients with BLBC
compared to non-BLBC using a panel of IHC stains.
Materials and Methods
Patients and Data Collection
We identified 523 cases of invasive breast cancer in the database of
our institution diagnosed between 2004 and 2006, for which paraffin
blocks were available. After obtaining approval from the institutional
review board, a retrospective chart review of patients’ demographic,
clinical, and pathological data was performed.
Patients who received preoperative treatment were excluded from
this study. Tumor histology, tumor grade, lymph node status, stage,
ER, PR, andHER2 status were determined from the original pathology
reports. Tumors had been diagnosed in our institution by experienced
pathologists using standard criteria for histology and modified Scarff-
Bloom-Richardson criteria for grade [23]. Based on the histologic sub-
type, tumors were assigned to one of the following groups: 1) invasive
ductal carcinoma not otherwise specified or any other special type of
invasive ductal carcinoma, 2) invasive lobular carcinoma, 3) mixed
ductal and lobular carcinoma, or 4) adenocarcinoma with spindle cell
metaplasia and metaplastic carcinoma.
Tumors were considered to be positive for ER or PR when nuclear
reactivity was observed in at least 1% of neoplastic cells with an in-
tensity of 3+ [24]. The expression of Her2 was classified according to
the Hercept Test assay’s scoring system, which includes four catego-
ries, namely, 0, 1+, 2+, and 3+, based on the intensity and propor-
tion of membrane staining in tumor cells. Positivity was defined as a
Her2 score of 3+ for immunostaining (>30% of the tumor cells show
circumferential intense and uniform staining) or a ≥2.2-fold increase
in Her2 gene amplification, as determined by fluorescence in situ
hybridization using the Vysis PathVysion Her-2 DNA Probe Kit
(Abbott Molecular, Inc, Abbott Park, IL) [25]. ER, PR, and Her2
tests were done at the time of initial diagnosis on needle core biopsies
or excision/mastectomy specimens, with a minimum 6-hour fixation
time in formaldehyde. The methodology and cutoffs for ER, PR,
and Her2 were the same for all the cases included in this study. Stage
of the tumor at diagnosis was assigned according to the American Joint
Committee on Cancer [26]. Follow-up for patients was obtained from
our Computer Information System records and the Surveillance
Epidemiology and End Results database. The overall survival was the
time, in months, from the date of the primary surgery to the time of
breast cancer–related death. The median and mean follow-up time was
41.1 months (range, 0-72 months) and 40.2 months, respectively.
Tissue Samples
The hematoxylin and eosin slides of all the cases were reviewed, and
appropriate areas from the tumors were selected for tissue microarray
construction (TMAs). TMAs were prepared using selected paraffin-
embedded blocks of tumor from each case. Two 1-mm cores were
obtained from each block. A total of 19 TMAs were performed. Each
TMA consists of 62 cores containing 2 cores from each patient and
normal tonsil and ovary as controls. This procedure has been validated
in previous breast cancer studies [27].
IHC Techniques
IHC stains including CK5/6, EGFR, p53, and Glut-1 were per-
formed on TMA sections. Five-micrometer-thick unstained sections
were placed onto glass slides, then deparaffinized in xylene, and rehy-
drated through a series of decreasing ethanol concentration. The sec-
tions were pretreated with hydrogen peroxide (3%) for 10 minutes to
remove the endogenous peroxidase, followed by antigen retrieval
through steam bath for 20 minutes in citrate buffer. The primary anti-
body was applied, followed by washing and incubation with the biotiny-
lated secondary antibody for 30 minutes at room temperature. Antigen
detection was carried out by placing diaminobenzidine on each section.
The slides were counterstained with hematoxylin and dehydrated in
alcohol and xylene before the slides were mounted. The characteristics
of the primary antibodies used in this study are listed in Table 1.
Evaluation of IHC Staining
The expression of CK5/6 and EGFR was designated as positive if
any cytoplasmic and/or membranous staining was observed [4]. Pos-
itivity for Glut-1 was defined as any detectable membranous staining
in tumor cells. In contrast, cases designated as −1–negative did not
reveal any IHC staining for Glut-1 [28,29]. The cutoff point between
Table 1. Characteristics of the Primary Antibodies.
Marker Clone Species Manufacturer* Dilution (Duration) Antigen Retrieval
ER ER-6F11 Mouse mAb Dako Predilute (32 min) Citrate buffer
PR PGR636 Mouse mAb Dako Predilute (32 min) Citrate buffer
Her2 CB11 Mouse mAb Dako Predilute (32 min) Citrate buffer
CK5/6 D5/16B4 Mouse mAb Cell Marque Predilute (32 min) Citrate buffer
EGFR 31G7 Mouse mAb Ventana Predilute (32 min) Citrate buffer
p53 DO-7 Mouse mAb Ventana Predilute (32 min) Citrate buffer
Glut-1 E308 Rabbit poly Dako 1:100 (1 h) Citrate buffer
mAb indicates monoclonal; poly, polyclonal.
*Dako, Carpinteria, CA; Cell Marque, Rocklin, CA; Ventana, Tucson, AZ.
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low and high p53 expression was 50% [30]. A positive control with a
tissue sample known to express the antigen of interest was included
with each stain. Red blood cells within tissue sections from a capillary
hemangioma case were used as positive controls for Glut-1. Three
pathologists (Y.H., R.A., and S.B.) individually evaluated the slides
blindly under a transmission light microscope. The concordance rate
was 90% between the three pathologists. In case of disagreement, the
slides were reviewed simultaneously by the three pathologists seated at a
multiheaded microscope with a resolution of the difference in opinion.
Definition of BLBC
There is no consensus on how to define BLBC based on immuno-
histochemistry. Most of the BLBCs lack the expression of ER, PR,
and Her2 and express one of the basal cytokeratins like CK5/6 or
CK17 [5–7]. Nielsen et al. [7] developed a classification based on
the lack of ER, PR, and Her2 expression, coupled with the expression
of CK5/6 and or EGFR. This panel identified gene expression–based
BLBC with a sensitivity of 76% and a specificity of 100%. Several
studies indicate that BLBC can be reliably defined by the absence
of ER, PR, and Her2 expression (i.e., triple-negative) and therefore
triple-negative and BLBC should be synonymous. Conversely, others
have proposed that a proportion of BLBCs may be positive for ER
and Her2 [9,10].
In this study, we defined BLBC using the criteria of Carey et al.
and others by the negativity to ER, PR, and Her2 plus the expression
CK5/6 and/or EGFR [7,31,32] (Figure 1).
Statistical Analysis
Statistical analysis was performed using SPSS version 17.0 (Chicago,
IL). χ2 and Fisher exact tests were used to study the statistical associa-
tion between clinicopathologic and IHC variables. Unpaired t test was
used for analysis of continuous variables. Survival times were estimated in
months from the date of diagnosis to the date of death or last follow-up.
Survival curves were plotted using the Kaplan-Meier method, and dif-
ferences in survival curves were assessed by the log-rank test. Statistical
significance was defined as a P < .05.
Results
We identified 523 cases of invasive breast carcinoma in the database
of our institution for which paraffin blocks and ER, PR, and Her2
markers were available. The mean age of patients was 56.9 years
(range, 26-94 years). The median follow-up time was 41.1 months
(range, 0-72 months). The clinicopathologic characteristics of all the
patients enrolled in this study are summarized in Table 2.
There was 20% loss of cases either due to loss of tissue cores dur-
ing processing or due to lack of tumor cells. The interpretable cases
were still representative of the total cases (423/523 cases) in various
clinicopathologic variables including age, tumor grade, stage, and
hormonal status.
The correlation of Glut-1 expression with various clinicopathologic
features and biologic markers is detailed in Table 3. There was a signif-
icant difference in the mean age at diagnosis between Glut-1–positive
Figure 1. Photomicrograph of a BLBC showing a high-grade invasive ductal carcinoma not otherwise specified, composed of broad sheets
of polygonal tumor cells, with marked pleomorphism and areas of necrosis. (A) Staining with hematoxylin-eosin stain (magnification, ×100).
Strong immunoreactivity of cytokeratin5/6 (B) and EGFR (C) in tumor cells (magnification, ×200).
Table 2. Clinicopathologic Characteristics in 523 Invasive Breast Carcinomas.
Age, mean ± SD, years 56.9 ± 11.7
Race, n (%)
African American 317 (60.6)
White 196 (37.5)
Others 10 (1.9)
Histologic grade, n (%)
1 32 (6.1)
2 128 (24.5)
3 311 (59.5)
Unknown 52 (9.9)
Histologic subtype,* n (%)
IDC 456 (87.9)
ILC 39 (7.5)
Mixed 18 (3.4)
Others 6 (1.1)
Tumor size, n (%), cm
<2 178 (34)
2-5 135 (25.8)
5-10 45 (8.6)
>10 18 (3.4)
Unknown 147 (28.2)
Stage, n (%)
I 128 (24.5)
II 177 (33.9)
III 92 (17.6)
IV 40 (7.6)
Unknown 86 (16.4)
ER, n (%)
Negative 203 (38.8)
Positive 320 (61.2)
PR, n (%)
Negative 156 (29.8)
Positive 367 (70.2)
Her2, n (%)
Negative 463 (88.5)
Positive 60 (11.5)
IDC indicates invasive ductal carcinoma; ILC, invasive lobular carcinoma.
*Data are lacking for some patients.
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and Glut-1–negative cases (mean age, 58.8 vs 55.1 years, respectively,
P = .02). Glut-1 positivity was significantly associated with invasive
ductal carcinoma, compared to invasive lobular carcinoma and mixed
ductal and lobular carcinoma (P < .001). Although the association
between Glut-1 expression and axillary lymph node status at diagnosis
was not significant (P = .09), tumors positive for Glut-1 were more
likely to be of negative lymph node status.
Glut-1 expression was significantly associated with high histologic
grade, ER negativity, PR negativity, CK5/6 positivity, EGFR expres-
sion, and high p53 expression (P < .001). There was no significant
association between Glut-1 expression and race, tumor size, pathologic
stage, and Her2 status.
When we defined BLBC by negativity to ER, PR, and Her2 plus
the expression CK5/6 and/or EGFR), 62 cases (14.7%) were catego-
rized as BLBC versus 361 (85.3%) non-BLBC (Figure 1). In this study,
we found a significant correlation between Glut-1 expression and
BLBC (Table 4). Glut-1 was expressed in 42 (76.4%) of 55 BLBCs,
whereas only 55 (23.8%) of 231 non-BLBCs showed expression for
Glut-1 (P < .001). Figure 2 shows a case of BLBC with positive
Glut-1 expression and a case of non-BLBC with negative Glut-1 stain-
ing. When we stratified both categories by grade, Glut-1 was still sig-
nificantly associated with BLBC. Among the poorly differentiated
tumors, Glut-1 was expressed in 71% of BLBCs versus 29% of non-
BLBCs (P < .001).
Glut-1 expression was associated with lower overall survival rate;
however, it did not reach significance. At 5 years, the overall survival
rate was 65.8% for patients with Glut-1–positive tumors versus 73.8%
for patients with Glut-1–negative tumors (P = .13; Figure 3). Similarly,
Table 3. Correlation of Glut-1 Expression with Clinicopathologic Characteristics and Biologic Markers.
Variable No. Patients Glut-1 Negative (n = 214, 65%) Glut-1 Positive (n = 115, 35%) P
Age, mean ± SD, years 329 58.8 ± 14.1 55.1 ± 13.4 .02
Race, n (%)
African American 193 116 (60.1) 77 (39.9) .07
White 129 93 (72.1) 36 (27.9)
Others 4 3 (75) 1 (25)
Histologic grade,* n (%)
1 25 19 (76) 6 (24) .01
2 81 61 (75.3) 20 (24.7)
3 191 108 (56.5) 83 (43.5)
Histologic subtype, n (%)
IDC 284 180 (63.4) 104 (36.6) <.001
ILC 26 25 (96.2) 1 (3.8)
Mixed 13 9 (69.2) 4 (30.8)
Others 6 0 6 (100)
Tumor size, n (%), cm
<2 130 77 (59.2) 53 (40.8) .14
2-5 60 39 (65) 21 (35)
5-10 22 17 (77.3) 5 (22.7)
>10 9 8 (88.9) 1 (11.1)
Lymph node,* n (%)
Negative 131 78 (59.5) 53 (40.5) .09
Positive 114 79 (69.3) 35 (30.7)
American Joint Committee on Cancer stage,* n (%)
1 76 53 (69.7) 23 (30.3) .35
2 98 57 (58.2) 41 (41.8)
3 41 29 (70.7) 12 (29.3)
4 8 5 (62.5) 3 (37.5)
ER, n (%)
Negative 102 40 (39.2) 62 (60.8) <.001
Positive 227 174 (76.7) 53 (23.3)
PR, n (%)
Negative 209 120 (57.4) 89 (42.6) <.001
Positive 120 94 (78.3) 26 (21.7)
Her2, n (%)
Negative 302 198 (65.6) 104 (34.4) .53
Positive 27 16 (59.3) 11 (40.7)
CK5/6,† n (%)
Negative 186 140 (75.3) 46 (24.7) <.001
Positive 126 63 (50) 63 (50)
EGFR,† n (%)
Negative 210 159 (75.7) 51 (24.3) <.001
Positive 92 39 (42.4) 53 (57.6)
p53,† n (%)
Low (<50%) 236 166 (70.3) 70 (29.7) <.001
High (>50%) 69 30 (43.5) 39 (56.5)
*Data are lacking for some patients.
†Some tissue cores are missing due to processing.
Table 4. Correlation of Glut-1 Expression with the Molecular Subtypes of Breast Cancer.
Glut-1, n (%) BLBC (n = 55, 19.5%) Non-BLBC (n = 231, 80.5%)
Positive 42 (76.4) 55 (23.8)
Negative 13 (23.6) 176 (76.2)
P <.001
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when we stratified BLBCs according to Glut-1 expression, there was no
significant difference in overall survival between the two groups (P = .08).
Discussion
The aim of this study was to compare the IHC expression of Glut-1
between BLBC and non-BLBC using a restricted panel of IHC stains.
In this report, we found significant correlation between Glut-1 expres-
sion and BLBC.
Basal increased glucose uptake and use is a major feature of malig-
nant tumors compared to normal tissue [33]. This uptake is mediated
by glucose transporters and regulated by endogens and growth factors
[34]. Glut-1 is one of the facilitative cell surface glucose transporter
family that function as an energy-independent system for transport of
glucose down a concentration gradient [11] and is dually controlled
through HIF-1 and in response to reduced oxidative phosphorylation
[14]. Overexpression of Glut-1 has been described in various malig-
nancies such as non–small cell lung carcinoma, colorectal carcinoma,
and gastric carcinoma; and it was associated with enhanced tumor
aggressiveness and poor outcome [17–19].
Previous studies on the expression of Glut-1 in breast cancer showed
that Glut-1 expression was associated with high nuclear grade, high
proliferative activity, and aggressive behavior [20–22]. We found that
Glut-1 expression was significantly associated with high histologic
grade, ER and PR negativity, and basal cytokeratins expression.
Younes et al. [22] found positive correlation between Glut-1 expres-
sion and nuclear grade. In contrast to our results, Glut-1 immunostaining
did not correlate with ER status. This contradictory result regarding ER
status could be explained due to the use of different techniques. They
assessed ER status using the dextran charcoal assay with sucrose gradi-
ent centrifugation method on frozen breast tissue. Kang et al. [35] dem-
onstrated that Glut-1 expression correlated significantly with high
nuclear grade, ER and PR negativity, overall survival, and disease-free
survival. In our study, Glut-1 expression was associated with lower
overall survival rate; however, it did not reach significance. This could
be explained by the relatively short follow-up time of our patients. Sim-
ilar to our results, both studies found that Glut-1 expression did not
correlate with tumor size and lymph node involvement.
There was a significant association between Glut-1 immunostaining
and high p53 expression, which is considered as a biological marker
of aggressiveness. It has been shown that the wild-type p53 represses
Glut-1 gene transcription; in contrast, the mutated p53 is associated with
up-regulation of the transcriptional activity of the Glut-1 gene promoters.
This, in turn, results in increased glucose metabolism and cell energy
supply, which would be predicted to facilitate tumor growth [36].
We found significant correlation between Glut-1 expression and
BLBC. BLBC has been characterized by expression of EGFR, c-kit,
VEGF, and higher incidence of p53 and breast cancer 1 (BRCA1)
mutations [4–7].
van der Groep et al. investigated the association between HIF-1
and Glut-1 with BRCA1 germline mutation–related breast cancer [37].
BRCA1 related breast cancers are often of high-grade, high-proliferative
activity, triple-negative phenotype and often express basal cytokeratins
(i.e., BLBC) [38–40]. Overexpression of Glut-1 and HIF-1 was signif-
icantly more frequent in BRCA1 germline mutation–related cancer, that
is, 27 of 30 (90%) versus 54 (29%) of 183 and 88 (44%) of 200 sporadic
control breast cancer cases [37].
Because chemotherapy is the only therapeutic option currently avail-
able for patients with BLBC, research during recent years has focused
on increasing knowledge about key pathways in BLBC aimed at dis-
covery of new treatment options. Novel targeted therapies (e.g., EGFR,
c-kit, and VEGF inhibitors alone or in combination with chemo-
therapy) have been investigated with mixed results [41–43].
Hypoxic pathways might be a potential target for this breast cancer
subtype. Pharmacological inhibition of glucose metabolism has been
shown to exhibit promising anticancer activity in vitro and in vivo,
alone or in combination with other therapeutic modalities. One
study showed that anti–Glut-1 antibodies inhibit proliferation and
Figure 2. (A) BLBC (invasive ductal carcinoma not otherwise specified) showing strong membranous staining for Glut-1 in tumor cells
(magnification, ×400). (B) Non-BLBC showing tumor cells with negative staining for Glut-1 (magnification, ×400).
Figure 3. Kaplan-Meier short-termoverall survival byGlut-1 expression.
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induce apoptosis in breast cancer cell lines. Furthermore, it showed
that anti–Glut-1 antibodies enhance apoptosis caused by chemo-
therapeutic agents like cisplatin, paclitaxel, and targeted agents like
gefitinib [44]. Glufosfamide is a cytotoxic agent delivered through
the glucose transport system. In a feasibility trial of this agent, com-
plete response was observed in pancreatic, colon, and breast cancer
patients [45]. Inhibition of expression or functionality of Glut-1,
rather than inhibiting glucose metabolism in its entirety may more
specifically target those cells within the tumor that depend on a high
rate of glucose uptake and glycolysis [46].
The current study has its limitations. These include 1) loss of
some cases either due to loss of tissue cores during processing or
due to lack of tumor cells, 2) the relatively short follow-up time of
our patients, and 3) the fact that the use of IHC to evaluate protein
levels does not always reflect the structure or functionality of the pro-
tein. However, the strength of our study lies in the fact that, to our
knowledge, the current study is the first to demonstrate an association
between Glut-1 expression and BLBC.
In conclusion, our results show that Glut-1 is significantly correlated
with BLBC and might be a potential therapeutic target for this aggres-
sive subtype of breast cancer, and this warrants further investigation.
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